Amphastar reported Q4 net revenues of USD 183.1 million (-2%) and GAAP net income of USD 24.4 million, or USD 0.51 per diluted share. Adjusted non-GAAP net income was USD 34.2 million, or USD 0.73 per diluted share. For FY 2025, Amphastar posted net revenues of USD 719.9 million (-2%) and GAAP net income of USD 98.1 million, or USD 2.03 per diluted share. Adjusted non-GAAP net income was USD 156.6 million, or USD 3.25 per diluted share. Cash flow provided by operating activities was USD 156.1 million. In product highlights, Q4 BAQSIMI revenue was USD 46.7 million (+12%). For FY 2025, BAQSIMI revenue was USD 185.4 million (+46%) and Primatene MIST revenue was USD 108.7 million (+7%), while epinephrine revenue was USD 70.6 million (-25%) and glucagon revenue was USD 69.1 million (-36%). Amphastar said it received FDA approvals for iron sucrose injection and teriparatide injection, and added three novel peptides plus a fully synthetic corticotropin compound through in-licensing to expand its proprietary pipeline. The company also noted that “other revenues” were no longer recorded in FY 2025 after it assumed global BAQSIMI distribution responsibilities at the beginning of 2025, with BAQSIMI-related revenues now recognized in product revenues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202602261605ACCESSWRNAPR_____1140804) on February 26, 2026, and is solely responsible for the information contained therein.